Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?
Arrowhead Pharmaceuticals (ARWR) has drawn investor attention after recent share price moves, with the stock up about 4.1% over the past day but down roughly 8.3% over the past month.
See our latest analysis for Arrowhead Pharmaceuticals.
The recent 1 day share price return of 4.1% comes after a softer 30 day share price return of 8.3% and a 9.6% share price return year to date. The 1 year total shareholder return of very large magnitude suggests Arrowhead Pharmaceuticals has already delivered a strong payoff for investors, and that short term momentum looks more mixed than the longer term picture.
If Arrowhead Pharmaceuticals has caught your eye, it can be useful to see what else is moving in healthcare, starting with a curated list of 39 healthcare AI stocks
After a sharp 1 year run and a recent pullback, Arrowhead Pharmaceuticals now sits between strong past gains and a more hesitant tape. The key question is whether it makes sense to step in here or wait for a cleaner entry on valuation grounds.
Most Popular Narrative: 16.6% Undervalued
On the most followed narrative, Arrowhead Pharmaceuticals screens as undervalued, with a fair value of $89.08 against the last close at $74.30. This puts the focus firmly on what is included in those long range assumptions.
Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for innovative treatments driven by an aging population and increasing prevalence of chronic and genetic diseases. This could significantly affect revenue growth as approvals and launches materialize.
Want to see what kind of revenue curve and margin shift that pipeline implies, and how that translates into a future earnings multiple on Arrowhead Pharmaceuticals?
Result: Fair Value of $89.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Arrowhead Pharmaceuticals story still hinges on successful late stage trial results and timely approvals, while rising R&D spending without marketed products keeps cash flow risk firmly in play.
Find out about the key risks to this Arrowhead Pharmaceuticals narrative.
Another Look At Arrowhead Pharmaceuticals Valuation
The earlier narrative leans on a fair value of $89.08, suggesting Arrowhead Pharmaceuticals is undervalued. On a simple P/S basis, though, the picture is less clear, with the current 16.8x ratio sitting above the US Biotechs industry at 11.1x and the fair ratio of 15.7x, which hints at some valuation stretch the market could move back toward. So is this a mispricing to lean into or a signal to be more patient?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Arrowhead Pharmaceuticals split between opportunity and caution, consider reviewing the underlying data now so you can weigh the 3 key rewards and 1 important warning sign: 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Arrowhead Pharmaceuticals?
If Arrowhead Pharmaceuticals has sharpened your focus, do not stop here. Broaden your watchlist with other stock ideas that match your goals and risk comfort.
- Tap into potential mispricings by scanning companies that trade below their assessed value using the 47 high quality undervalued stocks
- Strengthen your income stream by reviewing companies that offer robust payouts through the 8 dividend fortresses
- Prioritize resilience by focusing on companies with healthier financial profiles using the solid balance sheet and fundamentals stocks screener (47 results)
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com